Mathers_Cytokines

Scripts to reproduce main figures1-5.

Manuscript: Circulating Cytokine Associations with Clinical Outcomes in Melanoma Patients Treated with Combination Nivolumab plus Ipilimumab

Jiajia Chen15, Giuseppe Tarantino135, Mariano Severgnini*2, Joanna Baginska2, Anita Giobbie-Hurder4, Jason L. Weirather26, Michael Manos12, Janice D. Russell1, Kathleen Pfaff2, Scott J. Rodig2, Amy Y. Huang135, Ryan Brennick2, Matthew Nazzaro2, Emma Hathaway2, Marta Holovatska12, Claire Manuszak2, Srinika Ranasinghe2, David Liu&135, F. Stephen Hodi&123

Affiliations

1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2. Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA
3. Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA.
4. Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
5. Broad Institute of MIT and Harvard, Cambridge, MA, United States
6. Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.

*& contributed equally

Below is the description of figures that can be generated from the code:

Figure1. Association between cytokines levels and response to combination immune checkpoint blockade Figure2. Association of peripheral neutrophil and lymphocyte counts with response to therapy and survival. Figure3. An integrative analysis of the association between baseline chemokine CXCL6 and neutrophils related chemokines and cytokines; IL-10 and IL-23 correlated with other circulating cytokines Figure 4. Predicting response and survival with CXCL6, IL-10, and IL-23. Figure 5.The effect of prior IO treatment on cytokines and their associations with response.

Files

All data files will be made available in data folder upon acceptance of manuscript or reasonable request.

Contact

Jiajia Chen Email: jiajia_chen1@dfci.harvard.edu